The
global animal pharmaceuticals market was
valued at $12,614.3 million in 2015, and it is expected to grow at a CAGR of
7.7% during 2016 - 2022. The growth of the global market is largely driven by
increasing consumption of meat and milk, and increasing zoonotic and food borne
diseases. Due to growing health concern of related animals and their increasing
number, the healthcare expenses in farms are surging globally.
Request to Get the Sample
Report@ https://www.psmarketresearch.com/market-analysis/animal-pharmaceuticals-market/report-sample
Among
the different types of animal pharmaceutical products, the ectoparasiticides
generated largest revenue in the global animal pharmaceuticals market in 2015.
High prevalence of animals affected with ectoparasites is the key factor
driving the growth of the ectoparasiticides market. The bronchodilators market
would witness fastest growth during the forecast period.
Explore Full Report Description
At@ https://www.psmarketresearch.com/market-analysis/animal-pharmaceuticals-market
Based
on animal type, the largest revenue was generated from the sales of animal
pharmaceuticals for companion animals in 2015. Whereas, the animal
pharmaceuticals market for production animals would witness faster growth
during the forecast period. Increasing awareness regarding the livestock
related diseases is the key reason behind the higher growth of the animal
pharmaceuticals market for production animals.
Some
of the key players operating in the global market include Merck & Co. Inc.,
Vetoquinol S.A., Zoetis Inc., Virbac SA, Boehringer Ingelheim GmbH, Perrigo
Company plc, Eli Lilly and Company, Sanofi and Bayer AG.
